Tectonic Therapeutic, Inc. (TECX)
NASDAQ • Healthcare
Last close at September 14, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 51 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Tectonic Therapeutic beat EPS expectations in its preliminary fiscal second quarter of 2026 results reported Aug. 6, with a loss of $1.18 a share versus the $1.41 estimate, about +16%, and the figure was down 10.3% from a loss of $1.07 a year earlier. Operating income came in at a loss of about $24.2 million, while net income fell 11.5% to a loss of about $22.3 million from about $20.0 million a year ago. Operating cash flow was negative $39.9 million.
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. is a NASDAQ-listed biotechnology company that develops biologic therapies, mainly therapeutic proteins and antibodies, designed to regulate GPCR function. In qualitative terms, it is an early-stage drug developer focused on GPCR-targeted medicines and based in Watertown, MA.
Today's Snapshot
TECX opened flat at 29.71, while its sector was flat.
Trading Volume
Below 10d avg (153.1K)
21.2K
vs S&P 500 Today
Strong Underperformance
-3.01%
Updated: September 15, 2026 at 14:35 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$27.22 - $32.01Sell
- RSI (14)42.55Neutral
- Stochastic %K (14, 3, 3)6.92Buy
- MACD Level (12, 26)-1.02Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.